Johannes Levin
@johanneslevin.bsky.social
Professor for Clinical Neurodegeneration at LMU Munich; Deputy lead of clinical research at German Center for Neurodegenerative Diseases (DZNE), site Munich; Chief Medical Officer at MODAG GmbH. --> Passionate about therapy development, Bayern & Betis
It was a great honor to host the #GENFI summer meeting 2025. Two days of excellent talks and inspiring discussions. Thanks for coming to Munich and safe travels to everyone.
June 7, 2025 at 4:57 PM
It was a great honor to host the #GENFI summer meeting 2025. Two days of excellent talks and inspiring discussions. Thanks for coming to Munich and safe travels to everyone.
¡¡Día histórico para el Betis!! ¿Cómo va a quedar esto? ¡Vamos con todooo! 💚⚽️
What a historic day for Betis!! How’s this gonna end? Let’s gooo! 💚⚽️
What a historic day for Betis!! How’s this gonna end? Let’s gooo! 💚⚽️
May 28, 2025 at 10:11 AM
¡¡Día histórico para el Betis!! ¿Cómo va a quedar esto? ¡Vamos con todooo! 💚⚽️
What a historic day for Betis!! How’s this gonna end? Let’s gooo! 💚⚽️
What a historic day for Betis!! How’s this gonna end? Let’s gooo! 💚⚽️
TOPAS-MSA is launching in Japan. The investigator meeting took place yesterday and today in Yokohama. Japan’s strong tradition in MSA research and the outstanding dedication of the trial sites created an exciting environment. We’re thrilled to have you on board. clinicaltrials.gov/study/NCT065...
March 30, 2025 at 5:12 AM
TOPAS-MSA is launching in Japan. The investigator meeting took place yesterday and today in Yokohama. Japan’s strong tradition in MSA research and the outstanding dedication of the trial sites created an exciting environment. We’re thrilled to have you on board. clinicaltrials.gov/study/NCT065...
The TOPAS-MSA study investigating emrusolmin for disease modification in Multiple System Atrophy (MSA) is starting in Europe. Impressions from the investigator meeting in Barcelona (Spain).
www.clinicaltrials.eu/trial/study-of-emrusolmin-for-treating-adults-with-multiple-system-atrophy/
www.clinicaltrials.eu/trial/study-of-emrusolmin-for-treating-adults-with-multiple-system-atrophy/
February 12, 2025 at 2:42 PM
The TOPAS-MSA study investigating emrusolmin for disease modification in Multiple System Atrophy (MSA) is starting in Europe. Impressions from the investigator meeting in Barcelona (Spain).
www.clinicaltrials.eu/trial/study-of-emrusolmin-for-treating-adults-with-multiple-system-atrophy/
www.clinicaltrials.eu/trial/study-of-emrusolmin-for-treating-adults-with-multiple-system-atrophy/
So well deserved. An example to follow for all of us.
January 6, 2025 at 8:02 PM
So well deserved. An example to follow for all of us.